Piclidenoson

Drug Profile

Piclidenoson

Alternative Names: CF-101; IB-MECA; SI-615

Latest Information Update: 09 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Can-Fite BioPharma
  • Developer Can-Fite BioPharma; OphthaliX
  • Class Amides; Anti-inflammatories; Antineoplastics; Antirheumatics; Iodobenzenes; Neuroprotectants; Purine nucleosides; Ribonucleosides; Small molecules
  • Mechanism of Action Adenosine A3 receptor agonists; Apoptosis inhibitors; Immunosuppressants; Interleukin 17 receptor antagonists; Interleukin-23 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II/III Plaque psoriasis
  • Phase II Glaucoma; Rheumatoid arthritis
  • Phase I Uveitis
  • Preclinical Osteoarthritis
  • Discontinued Colorectal cancer; Dry eyes; Solid tumours

Most Recent Events

  • 07 Aug 2017 Can-Fite completes Human cardiodynamic safety trial for piclidenoson
  • 07 Aug 2017 Can-Fite plans the phase III COMFORT trial in Plaque psoriasis
  • 30 May 2017 Can-Fite plans to initiate a pivotal, registrational phase III study in Plaque psoriasis in H2 2017 (NCT03168256)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top